Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes-Reference-Cited by-同舟云学术

Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes

Published:2022-05-04 Issue:5 Volume:15 Page:501-513
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Lerma Edgar V.¹,Wilson Daniel J.²

Affiliation:

1. Section of Nephrology, University of Illinois at Chicago College of Medicine, Chicago, IL, USA

2. US Medical Affairs, Cardiovascular and Renal, Bayer US LLC, Pharmaceuticals, Whippany, NJ, USA

Funder

Rachel Mason and Lisa Moore of Envision Pharma Group

Bayer Corporation

Envision Pharma Group’s services complied with international guidelines for Good Publication Practice

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2022.2094770

Reference55 articles.

1. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns—NHANES 2007–2012

2. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States

3. Centers for Disease Control and Prevention. Chronic kidney disease in the United States, 2021 [cited 2021 Sept 15]. Available from: https://www.cdc.gov/kidneydisease/pdf/Chronic-Kidney-Disease-in-the-US-2021-h.pdf

4. Diabetic Kidney Disease

5. Cardiovascular Disease in Chronic Kidney Disease

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prioritizing the primary prevention of heart failure: Measuring, modifying and monitoring risk;Progress in Cardiovascular Diseases;2024-01

2. Sex-dependent effects of finerenone on hemostasis in normoglycemic and streptozotocin-induced diabetic mice;Biomedicine & Pharmacotherapy;2023-12

3. The role of mineralocorticoid receptors hyperactivation in the development of cardiorenal complications in patients with diabetes mellitus, perspective of the selective nonsteroidal mineralocorticoid receptors antagonist’s treatment: A review;Terapevticheskii arkhiv;2023-11-04

4. Non‐steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes;Diabetes, Obesity and Metabolism;2023-10-27

5. Association of metabolic syndrome and chronic kidney disease;Obesity Reviews;2023-10-02